Real-time · AI · Cross-signal
Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on Nxera Pharma Ltd. and Shionogi & Ltd — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Nxera Pharma and Shionogi's Partnership to Launch QUVIVIQ™ in Japan for Adults with Insomnia
Dec 19, 2024•over 1 year ago
Contract Type
partnership
TokyoBiotechnologyPharmaceuticalBiopharmaDescription
Nxera Pharma and Shionogi have announced the launch of QUVIVIQ™ (daridorexant) 25 and 50 mg in Japan for the treatment of adults with insomnia. Under the commercial partnership agreement, Shionogi will be solely responsible for the distribution and sales activities of QUVIVIQ™ in Japan, while Nxera Pharma's subsidiary will be the approval holder and be partially responsible for the provision of the drug product.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months